Zimmer Boosts Robotics: Acquires Monogram Technologies for $177M
Zimmer Biomet, a top name in musculoskeletal healthcare, just took a big step forward. On July 14, 2025, Zimmer announced it would buy Monogram Technologies for $177 million. This move strengthens Zimmer’s robotics game and promises exciting changes in orthopedic surgery.
The deal brings Monogram’s cutting-edge robotic tech into Zimmer’s fold. With the global robotics surgery market set to hit $16 billion by decade’s end, Zimmer aims to lead the pack. Readers will find key details here, from the price tag to what it means for the future.
This acquisition is not just about money; it’s about innovation. Zimmer plans to blend Monogram’s robots with its own systems, creating something unique. Stick around to learn how Zimmer is shaping the future of surgery.
Zimmer’s Big Buy: The Details
Zimmer Biomet agreed to buy Monogram Technologies for $177 million in cash. The deal offers Monogram shareholders $4.04 per share, a 22.8% jump from the last close. It also includes a bonus chance, up to $12.37 per share, if goals are met by 2030.
The purchase should wrap up later this year, if regulators and Monogram’s shareholders agree. Zimmer will use cash and debt to fund it. Both companies’ boards have already given the green light.
Why Zimmer Made This Move
Zimmer wants to grow its robotics offerings, and Monogram fits the bill. Monogram’s tech, cleared by the FDA in March 2025, helps with knee surgeries. Zimmer plans to pair it with its implants by early 2027.
This deal could make Zimmer the first to offer a fully independent surgical robot. More uses beyond knee surgery are coming by 2027. It’s a smart play to stay ahead in a fast-moving field.
What Monogram Brings to Zimmer
Monogram’s robots are semi and fully independent, guided by AI and CT scans. These will boost Zimmer’s ROSA® Robotics platform, already nearing 2,000 setups worldwide. Zimmer aims to offer options for all kinds of surgeries.
The mix covers robotic and non-robotic tools, with or without CT scans. Surgeons get more choices, which could draw more customers to Zimmer.
Zimmer’s Money Outlook
Zimmer expects this deal to keep earnings steady through 2027. Starting in 2028, profits should rise. Revenue will also pick up from 2027.
The investment should pay off with a solid return by year five. Zimmer sees this as a long-term win, matching the robotics market’s growth to $16 billion.
Recent Zimmer Numbers
- Q1 2025 revenue reached $1.909 billion, a 1.1% increase (or 2.3% excluding currency impact).
- Earnings per share (EPS) for Q1 stood at $1.81.
- For full-year 2025, Zimmer forecasts sales growth between 5.7% and 8.2%.
- Free cash flow is expected to drop to $750 million–$850 million.
- Full-year earnings guidance is now $7.90–$8.10, lowered due to tariff-related costs.
Final Thoughts
Zimmer Biomet’s buyout of Monogram Technologies is a bold step. It blends new tech with Zimmer’s strengths, aiming for a top spot in robotics surgery. With growth on the horizon, Zimmer is one to watch.
Disclaimer:
This content is for informational purposes only and not financial advice. Always conduct your research.